Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

New data for ddPCR usage
August 2017
SHARING OPTIONS:

HERCULES, Calif.—This year’s American Society of Clinical Oncology meeting saw Bio-Rad share research from two studies demonstrating how its Droplet Digital PCR (ddPCR) technology can be used to track patient response to immunotherapies. One study sought to differentiate between tumor growth and pseudoprogression, in which tumors appear to grow before shrinking after treatment. Dr. Jenny Lee used ddPCR to quantify BRAF and NRAS mutations in ctDNA in metastatic melanoma patients, and found that nine of 11 patients with pseudoprogressing tumors showed a significant decrease in ctDNA following immunotherapy treatment, while 18 of 20 with progressing tumors saw increased or stable ctDNA levels. Other work looked at the potential of using a blood-based biomarker identified by ddPCR to indicate treatment response in NSCLC patients. Dr. Jeroen Hiltermann and Ed Schuuring of the University Medical Center Groningen saw a spike in KRAS-mutated ctDNA in the blood of patients who responded to nivolumab, levels that later dropped until they were undetectable. The reaction corresponded with tumor response after just two weeks of treatment.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.